A test for early detection of first signs of maculopathy, especially for optometrists and ophthalmologists
Detect signs of Age-related Macular Degeneration (AMD) early to advise clients properly
Clients with early stages of AMD often see no restrictions in their vision. Therefore, they may not be aware of the beginning disease. This is where a screening test for macular degeneration can help.
The Macular Mapping Test 2.0 (MMT 2.0) was developed in the context of a German-American research project in 2005. It allows quick and clear detection of early signs of maculopathy. In addition, with the MMT 2.0 you can determine residual vision after an already diagnosed retinal diseases (age-related macular degeneration (AMD), diabetic retinopathy, etc.) and document the progression of the disease. This makes the Macular Mapping Test 2.0 (MMT 2.0) the ideal basis for consulting your clients.
A SIMPLE TEST FOR MACULAR DEGENERATION:
Example of a typical result obtained by the MMT 2.0 with variable stimulus intensity.
MMT 2.0 result chart with 100% contrast of the presented letter stimuli at up to 10deg eccentricity: Slight vision losses are indicated by gray and black dots. Very often, visual acuity shows no restrictions yet. Thus, a client might not show any abnormalities in a conventional visual acuity test.
MMT 2.0 result chart with 10% contrast of the presented letter stimuli at up to 10deg eccentricity: Due to the reduced contrast, a ring scotoma becomes visible. This means that first signs of a beginning macular degeneration may at first appear only parafoveally but would remain undetected by a conventional visual acuity test.
Early detection of these parafoveal abnormalities is very important, because it allows timely referal to an ophthalmologist, although the client may not yet notice any symptoms.